Evercore ISI analyst Elizabeth Anderson lowered the firm’s price target on Charles River (CRL) to $225 from $235 and keeps an Outperform rating on the shares ahead of Q3 earnings from the healthcare tech and distribution group. In the group, the firm’s top picks include CVS Health (CVS), its top large cap pick, Iqvia (IQV) and R1 RCM (RCM), the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CRL:
- Charles River announces opening of RightSourceSM laboratory in U.K.
- Charles River price target lowered to $209 from $212 at TD Cowen
- Charles River price target lowered to $275 from $280 at Wells Fargo
- Charles River price target lowered to $225 from $255 at Guggenheim
- Charles River price target lowered to $256 from $267 at Baird
